|
Microfluidic devices for circulating tumor cell capture
|
|
Funding: NYSTAR, NIH Clinical and Translational Science Center, Prostate Cancer Foundation
|
|
Rare cell capture from blood is exciting owing to the potential
to derive clinical benefit with minimal inconvenience and discomfort to patients.
Information derived from rare cells (e.g., fetal cells in mothers or cancer cells
in cancer patients) can be used in lieu of information from biopsies and thus
improve patient outcomes.
Microfluidic devices are ideally suited for these processes, owing to the
flexibility of geometric design, wealth of chemical manipulation techniques, and
assay compatibility of current systems. Stokes flow analysis is often a good predictor of the flows in these systems.
Our current work, in collaboration with Neil Bander, Evi Giannakakou, and David Nanus
at Weill Cornell Medical Center, is focused on microfluidic capture of circulating
tumor cells from prostate cancer patients with a view towards preclinical evaluation
of chemotherapeutic efficacy.
|
Publications and Presentations on Circulating Tumor Cell Capture
|
|
Pratt ED,
Huang C,
Hawkins BG,
Gleghorn JP,
Kirby BJ
"Rare cell capture in microfluidic devices, submitted, 2010.
|
 |
Gleghorn JP,
Pratt ED,
Denning D,
Liu H,
Bander NH,
Tagawa S,
Nanus DM,
Giannakakou PA,
Kirby BJ
"Capture of circulating tumor cells from whole blood of
prostate cancer patients using geometrically enhanced
differential immunocapture and a prostate-specific antibody",
Lab on a Chip, 10:27-29, 2010.
doi
pdf
|
|
Gleghorn JP,
Pratt ED,
Lofthus MS,
Levy BE,
Bander NH,
Nanus DM,
Giannakakou PA,
Kirby BJ
"High efficiency capture of circulating tumor cells
from patient blood using geometrically-enhanced differential immunocapture",
MicroTAS 2009, 1-5 Nov 2009, Jeju, Korea.
|
|
|
|
|
A microchip used to capture CTCs from the peripheral blood of
castrate-resistant prostate cancer patients.
|
|
|
|
|
A schematic of the size-dependent trajectories and surface collisions used in
geometrically enhanced differential immunocapture, which we use to capture circulating tumor cells
from the peripheral blood of
castrate-resistant prostate cancer patients.
|
|
|
|
